Intra-Cellular Therapies, Inc.
ORGANIC COMPOUNDS

Last updated:

Abstract:

The present invention relates to novel compounds having a capacity for PDE1 inhibition which may be used as tracers for use in diagnostic techniques, biomarkers for phosphodiesterase 1 (PDE1) in vivo, methods for treating and/or developing novel therapies for PDE1-associated conditions, and to methods of detection and treatment.

Status:
Application
Type:

Utility

Filling date:

10 Apr 2020

Issue date:

16 Jun 2022